Imaging in Stem Cell Transplant and Cell-based Therapy

86

63. Franssen LE, Raymakers RA, Buijs A, Schmitz MF, van Dorp S, Mutis T, et al. Outcome of
    allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma:
    long­term follow­up in a single institution. Eur J Haematol 2016 Mar 29.


64. Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, et  al. Reduced
    intensity­ conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or
    progressing after autologous transplantation: a study by the European Group for Blood and
    Marrow Transplantation. Bone Marrow Transplant. 2013;48(11):1395–400.


65. Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, et  al. Tandem
    autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity
    score analysis. Leuk Lymphoma. 2016;9:1–7.


66. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/
    reduced­intensity allogeneic stem cell transplantation vs autologous transplantation in multi­
    ple myeloma: long­term results of the EBMT­NMAM2000 study. Blood. 2013;121(25):
    5055–63.

S. Thanendrarajan and T.K. Garg